Want to see EOLS full AI Analyst Report?
EOLS Stock Chart & Stats
$8.88
$0.20(3.34%)
At close: 4:00 PM EDT
$8.88
$0.20(3.34%)
Day’s Range― - ―
52-Week Range$3.86 - $9.31
Previous Close$6.18
Volume650.24K
Average Volume (3M)1.05M
Market Cap
$517.84M
Enterprise Value$577.18
Total Cash (Recent Filing)$45.17M
Total Debt (Recent Filing)$164.80M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Nov 10, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding66,050,440
10 Day Avg. Volume880,374
30 Day Avg. Volume1,051,481
Financial Highlights & Ratios
PEG Ratio6.73
Price to Book (P/B)-18.55
Price to Sales (P/S)1.44
P/FCF Ratio-8.45
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.50Price Target Upside63.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.05
Revenue Forecast (FY)$334.34M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Raised GuidanceDouble-digit revenue growth and a higher 2026 outlook indicate sustained commercial momentum across Evolus’s portfolio. Meeting these targets would expand operating scale, support investment in newer products and international markets, and improve the company’s path toward durable profitability.
Portfolio Expansion And Customer LoyaltyGrowing adoption of both Jeuveau and Evolysse increases customer value and creates a broader platform for physician practices. Higher purchasing from multi-product accounts can strengthen retention, improve salesforce productivity, and support recurring expansion beyond the original toxin product.
Strong Margins And Improving EBITDAGross margins near 67%–69% provide a favorable product economics base, while consecutive quarters of positive adjusted EBITDA show improving operating leverage. Continued revenue scaling could allow fixed commercial costs to absorb more efficiently and support eventual sustained earnings generation.
Bears Say
Negative Equity And Rising DebtRising debt alongside negative equity leaves Evolus with a stressed capitalization profile and less flexibility to absorb setbacks. Debt reliance can constrain future investment choices, increase financing sensitivity, and make the transition to sustained profitability more important for balance-sheet stability.
Persistent Cash BurnThe core business continues to consume cash despite narrowing accounting losses, and free cash flow remains negative. Until operating cash flow turns sustainably positive, Evolus may need to rely on available facilities to fund expansion, interest costs and capital expenditures.
Revenue Concentration In ToxinsMost sales still come from the toxin category, so portfolio diversification has not yet materially reduced dependence on Jeuveau-related demand. Newer HA and international offerings may broaden the base over time, but their smaller current contribution leaves concentration as a durable business risk.
Evolus News
EOLS FAQ
What was Evolus Inc’s price range in the past 12 months?
Evolus Inc lowest stock price was $3.86 and its highest was $9.31 in the past 12 months.
What is Evolus Inc’s market cap?
Evolus Inc’s market cap is $517.84M.
When is Evolus Inc’s upcoming earnings report date?
Evolus Inc’s upcoming earnings report date is Nov 10, 2026 which is in 58 days.
How were Evolus Inc’s earnings last quarter?
Evolus Inc released its earnings results on Aug 05, 2026. The company reported $0.007 earnings per share for the quarter, beating the consensus estimate of -$0.033 by $0.04.
Is Evolus Inc overvalued?
According to Wall Street analysts Evolus Inc’s price is currently Undervalued.
Does Evolus Inc pay dividends?
Evolus Inc does not currently pay dividends.
What is Evolus Inc’s EPS estimate?
Evolus Inc’s EPS estimate is -0.07.
How many shares outstanding does Evolus Inc have?
Evolus Inc has 66,050,440 shares outstanding.
What happened to Evolus Inc’s price movement after its last earnings report?
Evolus Inc reported an EPS of $0.007 in its last earnings report, beating expectations of -$0.033. Following the earnings report the stock price went up 19.903%.
Which hedge fund is a major shareholder of Evolus Inc?
Currently, no hedge funds are holding shares in EOLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evolus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.50 (63.29% Upside)
$14.50 (63.29% Upside)
Blogger Sentiment
Bullish
EOLS Sentiment 100%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $949.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 8.3%
Last 30 Days ▲ 8.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.39%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
8.40%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Evolus Inc
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
EOLS Company Deck
EOLS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated clear operational momentum: double-digit top-line growth (21% in Q2, 14% year-to-date), third consecutive quarter of positive adjusted EBITDA, expanded international presence, new strategic licensing (ProFuelo) and an upwardly revised full-year revenue and margin outlook. These positives were tempered by sequential increases in operating expenses, modest absolute adjusted EBITDA, a decline in cash versus the prior quarter and ongoing tariff uncertainty that requires inventory repositioning. Given the company’s raised guidance, profitable growth trajectory, and strategic partnerships that expand the product portfolio, the highlights materially outweigh the lowlights.View all EOLS earnings summariesEOLS Stock 12 Month Forecast
Average Price Target
$14.50
▲(63.29% Upside)
Technical Analysis
Emergent Biosolutions
―
Rockwell Med
―
Organogenesis Holdings
―
Aquestive Therapeutics
―
Journey Medical Corp
―
Ownership Overview
2.83% Insiders
7.94% Mutual Funds
38.47% Other Institutional Investors
38.52% Public Companies and
Individual Investors